Parkinson's Disease Botanical and Natural Product Therapeutic Companies
Overview
flowchart TD
companies_pd_botanical_natural["PD Botanical and Natural Product Therapeutic Com"]
companies_pd_botanical_natural["Parkinson"]
companies_pd_botanical_natural -->|"related to"| companies_pd_botanical_natural
style companies_pd_botanical_natural fill:#81c784,stroke:#333,color:#000
companies_pd_botanical_natural["page"]
companies_pd_botanical_natural -->|"related to"| companies_pd_botanical_natural
style companies_pd_botanical_natural fill:#81c784,stroke:#333,color:#000
companies_pd_botanical_natural["catalogs"]
companies_pd_botanical_natural -->|"related to"| companies_pd_botanical_natural
style companies_pd_botanical_natural fill:#81c784,stroke:#333,color:#000
companies_pd_botanical_natural["biotechnology"]
companies_pd_botanical_natural -->|"related to"| companies_pd_botanical_natural
style companies_pd_botanical_natural fill:#81c784,stroke:#333,color:#000
style companies_pd_botanical_natural fill:#4fc3f7,stroke:#333,color:#000
This page catalogs biotechnology and pharmaceutical companies developing botanical extracts, herbal formulations, and natural product-based therapeutics for Parkinson's disease (PD). These companies leverage traditional medicine knowledge, plant-derived compounds, and natural product chemistry to develop disease-modifying and symptomatic treatments for PD.
...Parkinson's Disease Botanical and Natural Product Therapeutic Companies
Overview
Mermaid diagram (expand to render)
This page catalogs biotechnology and pharmaceutical companies developing botanical extracts, herbal formulations, and natural product-based therapeutics for Parkinson's disease (PD). These companies leverage traditional medicine knowledge, plant-derived compounds, and natural product chemistry to develop disease-modifying and symptomatic treatments for PD.
The field of botanical and natural product therapeutics for neurodegeneration draws from:
- Traditional medicine systems (Kampo, TCM, Ayurveda)
- Plant-derived bioactive compounds
- Standardized herbal extracts
- Phytochemical research and development
Japanese Kampo Medicine Companies
Tsumura & Co.
Headquarters: Tokyo, Japan
Founded: 1893
Website: [tsumura.co.jp](https://www.tsumura.co.jp)
Tsumura is Japan's leading Kampo (traditional Japanese medicine) pharmaceutical company, with over 130 years of experience in herbal formulation research and development. The company has expanded into neuroscience research, exploring how traditional medicine approaches can be integrated with modern drug discovery for neurodegenerative diseases.
Parkinson's Disease Program:
| Compound | Mechanism | Development Stage |
|----------|-----------|-------------------|
| TJ-200 | Neuroinflammation modulation | Discovery |
Tsumura's TJ-200 targets neuroinflammation, a key pathological feature in Parkinson's disease. The compound is derived from standardized Kampo formulations and represents the company's approach to applying modern scientific methods to traditional herbal medicine. [@tsumura]
Key Strengths:
- Over 130 years of Kampo formulation expertise
- GMP-certified manufacturing for herbal extracts
- Active compound identification from traditional formulations
- Strong academic partnerships with Japanese universities
See Also: [Tsumura](/companies/tsumura)
Nippon Shinyaku Co., Ltd.
Headquarters: Kyoto, Japan
Founded: 1919
Ticker: TSE: 4516
Nippon Shinyaku evolved from a traditional Japanese medicine manufacturer into a modern innovative pharmaceutical company. The company leverages its heritage in Kampo medicine combined with modern drug development capabilities, particularly in oligonucleotide therapies for rare diseases.
Parkinson's Disease Program:
| Compound | Mechanism | Development Stage |
|----------|-----------|-------------------|
| NS-205 | Alpha-synuclein aggregation inhibitor | Discovery |
NS-205 targets the alpha-synuclein aggregation pathway, a central mechanism in PD pathogenesis. The program represents Nippon Shinyaku's expansion from their traditional medicine roots into targeted neurodegeneration therapeutics. [@nippon]
Key Strengths:
- Heritage in Kampo medicine manufacturing
- Oligonucleotide technology platform
- Strong research partnerships with Kyoto University
- Established manufacturing capabilities
See Also: [Nippon Shinyaku](/companies/nippon-shinyaku)
Tree Pharmaceutical Co., Ltd.
Headquarters: Osaka, Japan
Founded: 2015
Tree Pharmaceutical is an Osaka-based biotechnology company dedicated to developing novel therapeutics for neurological and neurodegenerative diseases. The company collaborates with Japanese universities on natural product-based drug discovery.
Parkinson's Disease Program:
| Compound | Mechanism | Development Stage |
|----------|-----------|-------------------|
| TP-003 | Alpha-synuclein oligomerization inhibitor | Discovery |
TP-003 targets the toxic oligomerization of alpha-synuclein, which is believed to be the primary driver of dopaminergic neuron loss in Parkinson's disease. Tree Pharmaceutical's approach includes natural product screening and medicinal chemistry optimization. [@tree]
Key Strengths:
- Partnership with Tokyo University of Science for natural product discovery
- iPSC-derived neuron models for translational research
- Academic collaborations with Osaka University and Kyoto University
- [Mitochondrial](/mechanisms/mitochondrial-dysfunction) protection platform
See Also: [Tree Pharmaceutical](/companies/tree-pharmaceutical)
Indian Pharmaceutical Companies
Sun Pharmaceutical Industries Ltd.
Headquarters: Mumbai, India
Founded: 1983
NSE: SUNPHARMA
Sun Pharma is India's largest pharmaceutical company and a global leader in generic medications. The company produces a comprehensive portfolio of Parkinson's disease medications and is exploring novel therapeutic approaches.
Parkinson's Disease Products:
| Product | Type | Status |
|---------|------|--------|
| Levodopa/Carbidopa | Dopamine replacement | Marketed |
| Selegiline | MAO-B inhibitor | Marketed |
| Ropinirole | Dopamine agonist | Marketed |
| Pramipexole | Dopamine agonist | Marketed |
Sun Pharma's generic PD medications serve patients globally, providing access to essential dopamine replacement therapies. The company continues to expand its CNS portfolio with a focus on novel delivery systems and combination therapies. [@sun]
Key Strengths:
- Largest pharmaceutical company in India
- Global manufacturing and distribution network
- Broad CNS product portfolio
- Focus on affordable therapeutics
See Also: [Sun Pharmaceutical Industries](/companies/sun-pharma)
Research Landscape
Mechanisms of Interest
Companies in this space are targeting several key pathological mechanisms in PD:
Alpha-Synuclein Aggregation
- Compounds preventing toxic oligomer formation
- Agents promoting clearance of aggregates
Neuroinflammation
- Modulation of microglial activation
- Anti-inflammatory compounds from herbal extracts
Mitochondrial Dysfunction
- Compounds protecting mitochondrial function
- Antioxidant therapies from natural sources
Oxidative Stress
- Plant-derived antioxidant compounds
- Neuroprotective phytochemicals
Dopaminergic Neuron Protection
- Neurotrophic factors
- Neuronal survival compounds
Development Challenges
Companies developing botanical and natural product therapeutics face unique challenges:
- Standardization: Ensuring consistent potency and composition of natural product extracts
- Mechanism of Action: Characterizing complex multi-target effects of botanical formulations
- Clinical Development: Designing appropriate clinical trials for multi-component therapeutics
- Regulatory Pathways: Navigating regulatory frameworks for botanical drugs
- Quality Control: Maintaining batch-to-batch consistency
Emerging Trends
Growing Interest Areas
Kampo Medicine Modernization
- Scientific validation of traditional formulations
- Identification of active compounds
- Standardized extract development
Phytochemical Libraries
- High-throughput screening of plant compounds
- Natural product-inspired synthetic compounds
- Structure-activity relationship optimization
Combination Approaches
- Botanical formulations with standard PD medications
- Multi-target therapeutic strategies
Personalized Traditional Medicine
- Pharmacogenomic approaches to herbal therapeutics
- Patient stratification for treatment selection
Regional Companies Summary
| Company | Country | Primary Focus | PD Program Stage |
|---------|---------|---------------|------------------|
| Tsumura | Japan | Kampo formulations | Discovery (TJ-200) |
| Nippon Shinyaku | Japan | Kampo + modern pharma | Discovery (NS-205) |
| Tree Pharmaceutical | Japan | Natural products | Discovery (TP-003) |
| Sun Pharma | India | Generic medications | Marketed products |
Cross-Linking
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Alpha-Synuclein](/proteins/alpha-synuclein)
- [Neuroinflammation in PD](/mechanisms/pd-neuroinflammation)
- [Mitochondrial Dysfunction in PD](/mechanisms/pd-mitochondrial-dysfunction)
- [Japanese Neurodegeneration Biotech Companies](/companies/japanese-neurodegeneration-biotech)
- [PD Pipeline Companies](/companies/pd-pipeline-companies)
References
[Tsumura Corporate Information](https://www.tsumura.co.jp)
[Tree Pharmaceutical](https://www.tree-pharma.co.jp)
[Nippon Shinyaku](https://www.nippon-shinyaku.co.jp)
[Sun Pharmaceutical](https://www.sunpharma.com)Pathway Diagram
The following diagram shows the key molecular relationships involving PD Botanical and Natural Product Therapeutic Companies discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)